Alamar Biosciences’ NULISA Featured in 140+ Presentations at AAIC, Showcases eMTBR-Tau and BD-pTau217 Assays
ALMR•Alamar Biosciences’ NULISA platform is featured in more than 140 poster and session presentations at the Alzheimer’s Association International Conference in London July 12-15, quadrupling prior AAIC presence. A July 14 workshop will present data on eMTBR-Tau and BD-pTau217 assays measured alongside over 220 proteins, enhancing disease staging accuracy.
1. AAIC Presentation Uptake
Alamar’s NULISA platform will appear in over 140 posters and sessions at the Alzheimer’s Association International Conference in London from July 12-15, marking a fourfold increase from the previous event and signaling rapid adoption by the research community.
2. Workshop Highlights eMTBR-Tau and BD-pTau217 Data
On July 14, Alamar will host a workshop titled “Beyond p-tau217: Expanding Alzheimer’s Insights with Multiplex Protein Profiling,” showcasing eMTBR-Tau and BD-pTau217 assays measured alongside more than 220 disease-related proteins on a single NULISAseq panel.
3. Multiplex Profiling Advantages and Applications
Data to be presented demonstrate that combining BD-pTau217 and eMTBR-Tau improves discrimination across the Alzheimer’s continuum compared to single-analyte pTau-217, with applications spanning presymptomatic, prodromal and diagnosed populations and positioning NULISA as a leading multiplex profiling tool.
